These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 23101573)

  • 1. Atrial fibrillation: stroke prevention in older adults.
    Quinn GR; Fang MC
    Clin Geriatr Med; 2012 Nov; 28(4):617-34. PubMed ID: 23101573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?
    Lip GY
    J R Coll Physicians Edinb; 2012; 42 Suppl 18():35-44. PubMed ID: 22518392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C; Singh BN
    Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke risk assessment for atrial fibrillation: hospital-based stroke risk assessment and intervention program.
    Jackson SL; Peterson GM
    J Clin Pharm Ther; 2011 Feb; 36(1):71-9. PubMed ID: 21198722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticoagulants in patients with atrial fibrillation and end-stage renal disease.
    Brimble KS; Ingram AJ; Eikelboom JW; Hart RG
    Postgrad Med; 2012 Nov; 124(6):17-25. PubMed ID: 23322135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan.
    Lin LJ; Cheng MH; Lee CH; Wung DC; Cheng CL; Kao Yang YH
    Clin Ther; 2008 Sep; 30(9):1726-36. PubMed ID: 18840379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
    Själander A; Wallentin L; Rosenqvist M; Svensson P
    Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
    [No Abstract]   [Full Text] [Related]  

  • 11. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
    Lee BH; Park JS; Park JH; Park JS; Kwak JJ; Hwang ES; Kim SK; Choi DH; Kim YH; Pak HN
    J Cardiovasc Electrophysiol; 2010 May; 21(5):501-7. PubMed ID: 20021521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic treatment in atrial fibrillation.
    Lip GY; Boos CJ
    Postgrad Med J; 2008 May; 84(991):252-8. PubMed ID: 18508982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidental atrial fibrillation and its management.
    Saliba W
    Postgrad Med; 2011 Mar; 123(2):27-35. PubMed ID: 21474890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Confronting atrial fibrillation in the elderly: stroke risk stratification and emerging antithrombotic therapies.
    Strong SH; Halperin JL
    Geriatrics; 2007 Mar; 62(3):22-7. PubMed ID: 17346095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 19. Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice.
    Bajorek B; Magin PJ; Hilmer S; Krass I
    J Clin Pharm Ther; 2016 Aug; 41(4):432-40. PubMed ID: 27338004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
    Mant JW
    Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 39.